Microbiome characterization in patients with bronchiectasis and its association with severity and bronchial inflammation. Bronchi-Omics Project

Carvalho, Filipe Gonçalves Dos Santos; Comas, T Zapata; Pons, Laura; Blanca, S Quero; Portela, Esther Barreiro; Quin, L; Navarro, Annie; Amigó, J Pomares; Soler, Concepción Montón; Relat, Monserrat Vendrell; Castro, Gerard Muñoz; Polverino, E.; Casanoves, A Llunell; Cuartin, G Suarez; Acuña, Carmen Calero; Abad, Jorge; Gratacós, Antoni Rosell; Tapia, Alicia Marín

doi:10.1183/13993003.congress-2022.4594

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microbial dysbiosis in bronchiectasis activates host-immune and inflammatory responses and is associated with poor prognosis. Loss of alpha diversity is associated with disease severity, worse lung function, severe exacerbations and increased sputum production [ 96 ]. Respiratory microbiomes dominated by Pseudomonas and Aspergillus colonisation are associated with a higher frequency of exacerbations and greater disease severity compared to other microbiome profiles in bronchiectasis [ 96 , 97 ].…”

Section: Bronchiectasismentioning

confidence: 99%

“…Loss of alpha diversity is associated with disease severity, worse lung function, severe exacerbations and increased sputum production [ 96 ]. Respiratory microbiomes dominated by Pseudomonas and Aspergillus colonisation are associated with a higher frequency of exacerbations and greater disease severity compared to other microbiome profiles in bronchiectasis [ 96 , 97 ]. Haemophilus -dominant profiles are associated with an increase in airway inflammation ( e.g.…”

Section: Bronchiectasismentioning

confidence: 99%

See 1 more Smart Citation

ERS International Congress 2022: highlights from the Airway Diseases Assembly

et al. 2023

View full text Add to dashboard Cite

The European Respiratory Society (ERS) celebrated the return of an in-person meeting in Barcelona, Spain, after two years of virtual congresses. The congress programme was replete with symposia, skills workshops and abstract presentations from all 14 assemblies, encompassing over 3000 abstracts presented in the form of thematic poster discussion and oral presentations. In this article, highlights from this year's congress (including that from thematic poster sessions, oral presentations and symposia from keynote speakers), presented by Assembly 5: Airway diseases, Asthma, COPD and Chronic Cough, are reviewed by Early Career Members and experts in the field, with the aim of presenting key recent findings in the field.

show abstract

Section: Bronchiectasismentioning

confidence: 99%

Section: Bronchiectasismentioning

confidence: 99%

ERS International Congress 2022: highlights from the Airway Diseases Assembly

et al. 2023

View full text Add to dashboard Cite

show abstract

Infection and the microbiome in bronchiectasis

Mac Aogáin,

Dicker,

Mertsch

et al. 2024

Eur Respir Rev

View full text Add to dashboard Cite

Bronchiectasis is marked by bronchial dilatation, recurrent infections and significant morbidity, underpinned by a complex interplay between microbial dysbiosis and immune dysregulation. The identification of distinct endophenotypes have refined our understanding of its pathogenesis, including its heterogeneous disease mechanisms that influence treatment and prognosis responses. Next-generation sequencing (NGS) has revolutionised the way we view airway microbiology, allowing insights into the “unculturable”. Understanding the bronchiectasis microbiome through targeted amplicon sequencing and/or shotgun metagenomics has provided key information on the interplay of the microbiome and host immunity, a central feature of disease progression. The rapid increase in translational and clinical studies in bronchiectasis now provides scope for the application of precision medicine and a better understanding of the efficacy of interventions aimed at restoring microbial balance and/or modulating immune responses. Holistic integration of these insights is driving an evolving paradigm shift in our understanding of bronchiectasis, which includes the critical role of the microbiome and its unique interplay with clinical, inflammatory, immunological and metabolic factors. Here, we review the current state of infection and the microbiome in bronchiectasis and provide views on the future directions in this field.

show abstract

Microbiome characterization in patients with bronchiectasis and its association with severity and bronchial inflammation. Bronchi-Omics Project

Cited by 2 publications

References 0 publications

ERS International Congress 2022: highlights from the Airway Diseases Assembly

ERS International Congress 2022: highlights from the Airway Diseases Assembly

Infection and the microbiome in bronchiectasis

Contact Info

Product

Resources

About